ABT vs DXCM

Abbott Laboratories remains a highly stable and diversified global healthcare leader, further solidifying its position with the recent $23 billion Exact Sciences acquisition which boosts its cancer diagnostics segment and is expected to accelerate 2026 revenue growth. While the company demonstrates robust financial health, strong competitive moats (e.g., FreeStyle Libre), and strategic capital all...

Dexcom maintains its strong position as a Continuous Glucose Monitoring (CGM) market leader, driven by successful G7 global rollout and promising initial penetration of Stelo into the Type 2 non-insulin market. The company exhibits solid financial health, consistent operational execution (Q4 2025 earnings beat), and positive analyst sentiment with recent upgrades. The absence of previous concerns ...